ClinicalTrials.gg
CompletedNCT01206608Updated Mar 2, 2021Results posted

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

A Phase 2 interventional study of SKY0402 + bupivacaine HCl and Mid-dose SKY0402 + bupivacaine HCl in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
290th of 364
40 · median 70
Started
2008
with 8 others
Phase 2
43 of 364
4 open now
Registered
21st of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 290th largest by enrollment, is one of 9 that started in 2008, is one of 43 in phase 2, and was the 21st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study was to demonstrate the superiority of SKY0402 over conventional, commercially-available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local administration of the study drug.

Read the detailed description

This was a Phase 2, parallel-group, active-control, randomized, double-blind study conducted to evaluate a single local administration of low dose or high dose of SKY0402 compared with 75 mg of bupivacaine HCl (i.e., Marcaine® 0.5%) in women undergoing bilateral, cosmetic, sub-muscular, augmentation mammoplasty under general anesthesia. Each subject was to serve as her own control.

A total of 40 subjects were randomized in a 1:1 ratio to receive one of the following regimens:

  • Low-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.
  • Mid-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.

Study drug was administered locally into the breast implant pocket at the end of surgery. After surgery, subjects were to receive standard treatment with acetaminophen 1000 mg three times daily and rescue analgesia with immediate-release oxycodone, as needed, for breakthrough pain.

Assessments of postoperative pain were conducted through 96 hours. Safety assessments were conducted including monitoring of local and systemic adverse events (AEs).

03

Conditions studied

  • Postoperative Pain

Keywords

  • Breast augmentation
  • Pain
  • Analgesia
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who met all of the following criteria were eligible for inclusion in the study:

  1. Women, 18-40 years of age at the Screening Visit.
  2. , surgically sterile, or willing to use an acceptable means of for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
  3. Scheduled to undergo primary, bilateral, sub-muscular, augmentation mammoplasty under general anesthesia.
  4. American Society of Anesthesiology (ASA) Physical Class 1-3.
  5. Able and willing to comply with all study visits and procedures.
  6. Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
  7. Willing and capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • Subjects were not eligible for the study if they met any of the following criteria:

    1. Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
    2. Body weight less than 50 kilograms.
    3. History of or idiosyncratic reaction to amide-type local anesthetics or to opioid medication.
    4. Administration of an product within 30 days or 5 elimination half-lives of such investigational product, whichever was longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
    5. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
    6. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
    7. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicated an increased vulnerability to study drugs and procedures, and exposed the subject to an unreasonable risk as a result of participating in this clinical trial (e.g., severe hepatic insufficiency, hypotension, heart block, or severely impaired cardiac function).

      In addition, the subject was ineligible to receive study drug if she met the following criterion during surgery:

    8. Any event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postoperative course.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Low-dose SKY0402 + bupivacaine HCl

    Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402

    Drug: SKY0402 + bupivacaine HCl

  • Active comparator
    Mid-dose SKY0402 + bupivacaine HCl

    Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402

    Drug: Mid-dose SKY0402 + bupivacaine HCl

Interventions

  • DrugSKY0402 + bupivacaine HCl

    Drug page: Bupivacaine

    Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket

  • DrugMid-dose SKY0402 + bupivacaine HCl

    Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores

    Assessments of postoperative pain were conducted through 96 hours and included pain intensity at rest (NRS-R) and with activity (NRS-A). The prescribed activity was to consist of raising the arm, in full extension at the elbow and wrist, to a position parallel with the axis of the torso. Pain intensity was scored on an 11-point scale, where 0 = no pain and 10 = worst possible pain.

    Time frame: Through 96 hours postdose

Secondary outcomes

  1. Number of Participants With Adverse Events

    Adverse events were monitored through Day 8 and serious adverse events through Day 30.

    Time frame: Through 30 days postdose

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneLow-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HCl
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores

Assessments of postoperative pain were conducted through 96 hours and included pain intensity at rest (NRS-R) and with activity (NRS-A). The prescribed activity was to consist of raising the arm, in full extension at the elbow and wrist, to a position parallel with the axis of the torso. Pain intensity was scored on an 11-point scale, where 0 = no pain and 10 = worst possible pain.

Time frame:
Through 96 hours postdose
Reported as:
Mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores
Units on a scale*hoursLow-dose SKY0402 (150mg) + Bupivacaine HClMid-dose SKY0402 (300mg)+ Bupivacaine HCl
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores340.7 ± 141.6293.4 ± 194.2
SecondaryNumber of Participants With Adverse Events

Adverse events were monitored through Day 8 and serious adverse events through Day 30.

Time frame:
Through 30 days postdose

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-dose SKY0402 + Bupivacaine HCl—0/20 (0%)19/20 (95%)
Mid-dose SKY0402 + Bupivacaine HCl—1/20 (5%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventLow-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HCl
Postprocedural hematomaInjury, poisoning and procedural complications0/201/20
Most frequent other events
Most frequent other events
EventLow-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HCl
NauseaGastrointestinal disorders16/2013/20
ConstipationGastrointestinal disorders8/204/20
Back painMusculoskeletal and connective tissue disorders5/201/20
TachycardiaCardiac disorders4/200/20
HeadacheNervous system disorders4/201/20
VomitingGastrointestinal disorders3/203/20
DizzinessNervous system disorders2/201/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HClTotal
<=18 years000
Between 18 and 65 years202040
>=65 years000
Age, Continuous
Age, Continuous(years)Low-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HClTotal
Mean30.7 ± 728.4 ± 629.6 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)Low-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HClTotal
Female202040
Male000
Region of Enrollment
Region of Enrollment(participants)Low-dose SKY0402 + Bupivacaine HClMid-dose SKY0402 + Bupivacaine HClTotal
United States202040
08

Study locations

1 site
  • Associates for Plastic Surgery
    La Jolla, California 92037, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Aug 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2010
First posted
Sep 22, 2010
Start
Mar 2008
Primary completionActual
Aug 2008
CompletionActual
Dec 2008
Results delay requested
Sep 22, 2010
Results first posted
Aug 6, 2013
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01206608
Responsible party
Sponsor
First posted
Sep 22, 2010
Start date
Mar 2008
Primary completion
Aug 2008
Completion
Dec 2008
Results posted
Aug 6, 2013
Last update
Mar 2, 2021

Study contacts

Kay Warnott, RN, ACNP
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion